MultiPoint Pacing IDE Study (MPP IDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01786993
Recruitment Status : Completed
First Posted : February 8, 2013
Results First Posted : September 30, 2016
Last Update Posted : May 15, 2018
Information provided by (Responsible Party):
St. Jude Medical

Brief Summary:

This IDE study is a prospective, randomized, double-blind, multi-center clinical study to evaluate the safety and efficacy of patient treatment with MPP compared to patient treatment with standard BiV pacing at 9 months.

The study will be conducted at a maximum of 50 investigational centers located in the United States. A maximum of 506 subjects implanted with the Quadripolar cardiac resynchronization therapy device (CRT-D) system will be enrolled in the study.

Condition or disease Intervention/treatment Phase
Heart Failure Device: MultiPoint Pacing Device: Traditional Biventricular Pacing Phase 3

Detailed Description:

All subjects will undergo a 2 dimensional Echocardiogram within the 30 days prior to implant, and again at 3, 6 and 9 months post implant. At implant, the final LV pacing configuration is programmed using any one of the 10 available pacing vectors. The paced/sensed atrioventricular (AV) and interventricular (VV) delays may be optimized as per the site's standard of care. Subjects will continue to receive BiV therapy until the 3-month follow-up visit.

At the 3-month visit, responder status between Enrollment and 3 months will be assessed using the Clinical Composite Score (CCS). All subjects that are "Improved" using the definition outlined in the CCS will be grouped together as Responders. All subjects that are "Worsened" or "Unchanged" using the definitions outlined in the CCS will be considered as Non-responders. All subjects will undergo acute measurement of cardiac performance (e.g., Echocardiography) at various MPP combinations compared to BiV pacing. Only subjects with "equal or better" echocardiographic measurements (i.e., EA VTI measurements) with MPP feature on compared to BiV pacing will be randomized in a 1:1 ratio to one of the two arms - BiV arm or MPP arm.

At the 9-month visit, responder status will be evaluated once again using the CCS and compared to the status at 3 months.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 506 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: MultiPoint Pacing IDE Study
Actual Study Start Date : April 2013
Actual Primary Completion Date : April 2015
Actual Study Completion Date : June 2016

Arm Intervention/treatment
Experimental: Multi-point pacing arm
MultiPoint Pacing
Device: MultiPoint Pacing
Subjects are programmed to MPP between 3 and 9 months. MPP programming is stipulated by the Echocardiographic measurements (e.g. EA VTI) during an acute hemodynamic assessment at the 3-month visit in the MPP IDE study.
Active Comparator: Biventricular arm
Traditional Biventricular Pacing
Device: Traditional Biventricular Pacing
Subjects are programmed to Quadripolar BiV pacing between 3 and 9 months using any of the 10 vectors available.

Primary Outcome Measures :
  1. Freedom From System-related Complications Through 9 Months Compared to an Objective Performance Criterion [ Time Frame: Implant to 9 months ]
    A system related complication is a complication related to the Quadripolar CRT-D device system which includes pulse generator and leads, as adjudicated by an independent Clinical Events Committee (CEC). All subjects who had an attempted implant or a successful Quadripolar system implant were included in the analysis of this safety endpoint.

  2. Percentage of Non-responders With MPP Compared to Biventricular Pacing [ Time Frame: 3 months to 9 months ]

    The hypothesis is that the non-response rate to CRT therapy in the MPP therapy arm is not inferior to the non-response rate in the BiV arm between 3 and 9 months post-implant. Responder status was assessed using the Clinical Composite Score (CCS). A patient's CCS was classified as worsened, improved or unchanged based on the definitions below:

    • Worsened - patient died due to cardiovascular reasons, experienced a HF event, demonstrated worsening in NYHA class, or had worsening of PGA score compared to the last observation
    • Improved - patient survived without a HF event, and demonstrated either improvement in NYHA class or improvement in PGA score, or both compared to the last observation.
    • Unchanged - patient was neither improved nor worsened

    For patients who were responders at the 3-month visit, those who were "Improved" and "Unchanged" between 3 and 9 months were classified as responders, whereas those who were "Worsened" were grouped together as non-responders.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meets current clinical indication for implantation of a cardiac resynchronization therapy system for treatment of heart failure or life-threatening ventricular tachyarrhythmia(s)
  • Receiving a new CRT implant or undergoing an upgrade from an existing ICD or pacemaker implant with no prior LV lead placement
  • Have the ability to provide informed consent for study participation and are willing and able to comply with the prescribed follow-up tests and schedule of evaluations

Exclusion Criteria:

  • Have had a recent Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA) within 3 months of enrollment
  • Have an existing Class I recalled lead
  • Have a hypersensitivity to a single 1.0mg dose of dexamethasone sodium phosphate
  • Have a classification of Status 1 for cardiac transplantation or consideration for transplantation over the next 9 months
  • Have permanent atrial fibrillation (AF)
  • Have undergone a cardiac transplantation within 40 days of enrollment
  • Have had a recent myocardial infarction, unstable angina within 40 days or cardiac revascularization within 3 months of implant.
  • Are currently participating in a clinical investigation that includes an active treatment arm
  • Are pregnant or planning to become pregnant during the duration of the study
  • Have a life expectancy of less than 9 months due to any condition
  • Are less than 18 years of age

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01786993

  Hide Study Locations
United States, Alabama
Heart Center Research, LLC.
Huntsville, Alabama, United States, 35801
United States, Arizona
Banner Heart Hospital
Mesa, Arizona, United States, 85027
United States, Arkansas
Arkansas Heart Hospital
Little Rock, Arkansas, United States, 72211
United States, California
Glendale Memorial Hospital and Medical Center
Glendale, California, United States, 91206
Scripps Green Hospital
La Jolla, California, United States, 92037
Premier Cardiology, Inc
Newport Beach, California, United States, 92663
Regional Cardiology Associates
Sacramento, California, United States, 95819
Sutter Memorial Hospital
Sacramento, California, United States, 95819
United States, Colorado
Colorado Heart & Vascular, P.C.
Lakewood, Colorado, United States, 80228
United States, Connecticut
Cardiology Associates of Fairfield County, PC
Norwalk, Connecticut, United States, 06851
United States, Delaware
Christiana Hospital
Newark, Delaware, United States, 19718
United States, Florida
Bay Area Cardiology Associates PA
Brandon, Florida, United States, 33511
Watson Clinic Center
Lakeland, Florida, United States, 33805
Florida Hospital Orlando
Orlando, Florida, United States, 32803
Sarasota Memorial Hospital
Sarasota, Florida, United States, 34239
United States, Georgia
St. Joseph's Hospital
Atlanta, Georgia, United States, 30342
United States, Illinois
HeartCare Midwest
Peoria, Illinois, United States, 61614
United States, Kentucky
Central Baptist Hospital
Lexington, Kentucky, United States, 40503
United States, Louisiana
Ochsner Medical Center
New Orleans, Louisiana, United States, 70121
United States, Massachusetts
Lahey Clinic Medical Center
Burlington, Massachusetts, United States, 01805
United States, Michigan
Thoracic Cardio Healthcare Foundation
Lansing, Michigan, United States, 48910
United States, Mississippi
Jackson Heart Clinic
Jackson, Mississippi, United States, 39216
North Mississippi Medical Center
Tupelo, Mississippi, United States, 38801
United States, Missouri
St. Luke's Hospital
Kansas City, Missouri, United States, 64111
Mercy Hospital St. Louis
Saint Louis, Missouri, United States, 63141
United States, New Jersey
Deborah Heart and Lung Center
Browns Mills, New Jersey, United States, 08015
Englewood Hospital and Medical Center
Englewood, New Jersey, United States, 07631
Morristown Memorial Hospital
Morristown, New Jersey, United States, 07962
United States, New Mexico
New Mexico Heart Institute
Albuquerque, New Mexico, United States, 87102
United States, New York
New York Presbyterian Hospital/Cornell University
New York, New York, United States, 10021
University of Rochester Medical Center
Rochester, New York, United States, 14642
United States, North Carolina
Novant Health Heart and Vascular Research Institute
Charlotte, North Carolina, United States, 28204
Wake Forest University Medical Center Clinical Sciences
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
The Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Ohio Health Research Institute
Columbus, Ohio, United States, 43124
The Toledo Hospital
Toledo, Ohio, United States, 43606
United States, Pennsylvania
Lancaster General Hospital
Lancaster, Pennsylvania, United States, 17602
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
WellSpan Health
York, Pennsylvania, United States, 17403
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Tennessee
St. Thomas Hospital
Nashville, Tennessee, United States, 37205
Vanderbilt Heart and Vascular Institute
Nashville, Tennessee, United States, 37232
United States, Texas
Cardiology Center of Amarillo, L.L.P
Amarillo, Texas, United States, 79106
Austin Heart
Austin, Texas, United States, 78756
South Texas Cardiovascular Consultants
San Antonio, Texas, United States, 78201
United States, Virginia
Cardiovascular Associates, LTD
Virginia Beach, Virginia, United States, 23454
United States, Wisconsin
Aurora Medical Group
Milwaukee, Wisconsin, United States, 53215
Aspirus Wausau Hospital
Wausau, Wisconsin, United States, 54401
Sponsors and Collaborators
St. Jude Medical
Principal Investigator: Gery Tomassoni, MD Central Baptist Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: St. Jude Medical Identifier: NCT01786993     History of Changes
Other Study ID Numbers: 60029161/D
First Posted: February 8, 2013    Key Record Dates
Results First Posted: September 30, 2016
Last Update Posted: May 15, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The study results will be presented at HRS Late-Breaking Clincial Trials Session in May, 2016

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases